Press coverage about Horizon Therapeutics (NASDAQ:HPTX) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Horizon Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 48.1310077735447 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Horizon Therapeutics stock opened at $45.99 on Friday. Horizon Therapeutics has a 12-month low of $20.23 and a 12-month high of $46.96.
ILLEGAL ACTIVITY NOTICE: “Horizon Therapeutics (NASDAQ:HPTX) Getting Somewhat Favorable Media Coverage, Study Finds” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/04/21/horizon-therapeutics-hptx-earns-daily-coverage-optimism-rating-of-0-06.html.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.